See Which Of The Latest 13F Filers Holds ABBV

Analysis of 13F filings for the 12/31/2024 reporting period indicates a notable increase in institutional ownership of AbbVie Inc (ABBV), with hedge funds collectively raising their aggregate holdings by 2.82%, or 34.8 million shares, from Q3 to Q4 2024. This broad accumulation across a large sample of funds, despite the inherent limitations of 13F data only disclosing long positions, suggests a growing institutional conviction in the pharmaceutical giant.

Analysis

Analysis of 13F filings for the quarter ending December 31, 2024, reveals a significant and broad-based increase in institutional ownership of AbbVie Inc. (ABBV). Across all reporting funds surveyed, aggregate holdings grew by 34,803,141 shares, a 2.82% increase from the previous quarter, indicating a strong positive shift in institutional sentiment. While the report correctly notes that 13F filings only capture long positions and can be misleading for individual funds, the aggregate accumulation across 7,884 filers provides a compelling directional signal. A smaller, recent sample of 20 funds further illustrates this trend, with a net increase of over 1.35 million shares, largely driven by a substantial position increase from Mackenzie Financial Corp. The continued presence of major institutions like Vanguard, BlackRock, and State Street as the top three holders solidifies ABBV's status as a core institutional holding, with recent data pointing toward active accumulation on top of this passive base.

Key Decisions for Investors

• The 2.82% quarter-over-quarter increase in aggregate institutional holdings is a bullish signal, suggesting investors should view the stock constructively and prioritize it for further fundamental research.
• Given that this analysis is based on lagging 13F data, investors should investigate the underlying corporate or market catalysts that likely drove this institutional accumulation during the fourth quarter.